Blake Borgeson, Director at RECURSION PHARMACEUTICALS, INC. (RXRX), sold 22,894 shares at $7.64 ($175K) on 2024-11-12, disclosed to the SEC on 2024-11-14.
Scheduled sale ($175k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.64 | 11,447 | $87K | 50.0% |
| 2 | $7.64 | 11,447 | $87K | 50.0% |
| Total | $7.64 avg | 22,894 | $175K | 100% |
| Filing → |
| RXRX | SELL | 2026-08-06 | $98K | — | Filing → |
| RXRX | SELL | 2026-07-09 | $159K | — | Filing → |
| RXRX | SELL | 2026-06-04 | $110K | — | Filing → |